RecruitingNCT06485271

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Sponsor

Changzhi People's Hospital Affiliated to Changzhi Medical College

Enrollment

504 participants

Start Date

Nov 1, 2023

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer RWS PD-1 Immunotherapy

Summary

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is looking at how well the immunotherapy drug camrelizumab — used alone or combined with apatinib (a targeted therapy) or chemotherapy — works for people with advanced gastric (stomach) cancer in everyday clinical practice. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced stomach cancer confirmed by a tissue biopsy - Your cancer has progressed or come back more than 6 months after completing chemotherapy - You have at least one measurable tumor on imaging - Your doctor has determined camrelizumab or apatinib is appropriate for your treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have previously received immunotherapy drugs (e.g., PD-1 or PD-L1 inhibitors) or anti-angiogenic drugs like apatinib - Your doctor determines you are not a suitable candidate for inclusion Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.